Pelthos Therapeutics Inc. (NASDAQ:PTHS) is a company operating in the biotechnology sector, focusing on developing innovative therapies. The company is currently facing challenges in generating returns that exceed its cost of capital. This is evident from its Return on Invested Capital (ROIC) of -21.33% compared to a Weighted Average Cost of Capital (WACC) of 24.01%, resulting in a ROIC to WACC ratio of -0.89.
Pelthos's negative ROIC indicates that the company is not efficiently using its capital to generate profits. This is a concern for investors as it suggests that the company is not covering its cost of capital, which is crucial for sustainable growth. The negative ROIC to WACC ratio further highlights this inefficiency in capital utilization.
In comparison, Azitra, Inc. (AZTR) has an even more concerning ROIC of -494.84% against a WACC of 3.96%, leading to a ROIC to WACC ratio of -124.87. This suggests that Azitra is significantly underperforming in terms of capital efficiency. Similarly, Silexion Therapeutics Ltd. (SLXN) also shows a negative ROIC of -363.40% with a WACC of 4.44%, resulting in a ROIC to WACC ratio of -81.82.
On the other hand, Longevity Health Holdings Inc. (XAGE) is a standout performer with a positive ROIC of 185.17% and a WACC of 5.43%, leading to a ROIC to WACC ratio of 34.11. This indicates that XAGE is effectively generating returns well above its cost of capital, showcasing efficient capital utilization and strong growth potential.
